Pilot Study of the Effects of Epidermal Growth Factor Receptor (EGFR) Inhibitors on the EGFR in Skin Lesions
- Determine the effects of EGFR inhibitors on the EGFR pathway in the skin of cancer
patients prior to and after receiving EGFR inhibitors (i.e., tyrosine kinase inhibitors
and monoclonal antibodies).
- Compare the effects of EGFR tyrosine kinase inhibitors vs monoclonal antibodies on the
EGFR pathway in the skin of these patients.
- Compare changes in the EGFR pathway with grade of rash in these patients.
- Compare changes in EGFR pathway effectors in the skin with serum TGFα levels in these
OUTLINE: This is a pilot study.
Patients undergo skin punch biopsies and blood sample collection at baseline, within 1 week
of developing skin rash, and 6 weeks after beginning treatment. Samples are analyzed by
immunohistochemistry and western blot for phosphorylated MAP kinase, AKT, and EGF levels and
TGFα levels. Patients also complete diagrams to indicate locations of the rash once weekly
during the first 6 weeks of treatment.
Observational Model: Case-Only, Time Perspective: Prospective
Effects of EGFR inhibitors on the EGFR pathway in the skin prior to and after receiving EGFR inhibitors
baseline and at 6 weeks
Laura Goff, MD
Vanderbilt-Ingram Cancer Center
United States: Federal Government
VICC GI 0561
|Vanderbilt-Ingram Cancer Center||Nashville, Tennessee 37232-6838|